Loading...
•
Jun 30, 2024
Leap Therapeutics Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024.
Key Takeaways
Leap Therapeutics reported a net loss of $20.4 million for the second quarter of 2024, compared to a net loss of $13.4 million for the same period in 2023. Research and development expenses increased to $17.9 million, driven by higher clinical trial costs. Cash and cash equivalents totaled $78.5 million at the end of the quarter.
Net loss for Q2 2024 was $20.4 million, compared to $13.4 million in Q2 2023.
Research and development expenses increased to $17.9 million, driven by clinical trial costs.
General and administrative expenses decreased to $3.4 million from $3.6 million in the same period last year.
Cash and cash equivalents totaled $78.5 million as of June 30, 2024.
Forward Guidance
Leap Therapeutics is positioned to achieve critical company milestones with the momentum provided by a $40 million private placement. Initial data from two randomized controlled studies are expected over the next 12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...